Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00129844
Other study ID # PCYC-0227
Secondary ID
Status Completed
Phase Phase 2
First received August 10, 2005
Last updated August 19, 2008
Start date September 2005
Est. completion date December 2007

Study information

Verified date August 2008
Source Pharmacyclics
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the effect of MGd in non-small-cell lung cancer (NSCLC) when given alone, and to evaluate the difference between two dosing regimens.


Description:

Outline:

Two-arm, open-label, randomized, 2-stage Phase II trial. Patients will be randomized on the first stage to 1 of 2 treatment arms:

Arm A - 10 mg/kg MGd once per week

Arm B - 15 mg/kg MGd once every 3 weeks

Patients will be treated on 3 week cycles, up to a maximum of 8 cycles (24 weeks). Patients with either objective response or stable disease after 2 cycles will receive up to 8 cycles of therapy. Patients with progressive disease will be terminated from the study.

At the end of Stage I, both treatment arms will be evaluated, and only the arm(s) that demonstrate at least one response (Complete Response or Partial Response) will proceed to Stage II. If both arms demonstrate a response, then both will proceed to Stage II.


Recruitment information / eligibility

Status Completed
Enrollment 108
Est. completion date December 2007
Est. primary completion date June 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- >18 years old

- Histologically or cytologically confirmed diagnosis of NSCLC

- Unresectable locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC patients who have received one prior platinum-based chemotherapy regimen

- Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria

- ECOG performance status score of 0 or 1

- Willing and able to provide written informed consent

Exclusion Criteria:

- Laboratory values of:

- Absolute neutrophil count < 1500/ul;

- Platelet count < 75,000/ul;

- Hemoglobin < 10 gm/dl;

- AST or ALT > 3 x the upper limit of normal (ULN);

- Alkaline phosphatase > 5 x ULN;

- Bilirubin > 2 x ULN;

- Serum creatinine > 2.0 mg/dL.

- Symptomatic or uncontrolled (untreated or treated and progressing) brain metastasis.

- Evidence of meningeal metastasis.

- Greater than one prior cytotoxic regimen (not counting adjuvant or neoadjuvant cytotoxic chemotherapy if completed > 12 months prior to cytotoxic regimen).

- Chemotherapy, radiation therapy, experimental therapy, immunotherapy or systemic biologic anticancer therapy within 21 days before beginning study treatment.

- Significant weight loss > 10% of body weight in preceding 6 weeks.

- Treatment for another cancer within 3 years of enrollment, unless basal cell carcinoma or cervical cancer in situ.

- Myocardial infarction within 6 months of enrollment or congestive heart failure rated New York Heart Association (NYHA) Class III or IV.

- Uncontrolled hypertension (systolic blood pressure > 160 mm Hg and diastolic blood pressure > 110 mm Hg on maximal medical therapy).

- Known history of porphyria (testing not required at screening visit).

- Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency (testing not required at screening visit).

- Known history of HIV infection (testing not required at screening visit).

- Female who is pregnant or lactating (serum pregnancy test is required for all female patients of childbearing potential).

- Sexually active male or female of childbearing potential unwilling to use adequate contraceptive protection.

- Physical or mental condition that makes patient unable to complete specified follow-up assessments.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Motexafin Gadolinium


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Pharmacyclics

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary To estimate the response rates of two different MGd dosing regimens for the treatment of NSCLC
Secondary To select the most effective regimen based on tumor response
Secondary To estimate the time to progression
Secondary To estimate survival
Secondary To evaluate the safety and tolerability of 2 dosing regimens of MGd in NSCLC patients
See also
  Status Clinical Trial Phase
Recruiting NCT03357094 - Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function N/A
Recruiting NCT05543954 - 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients Early Phase 1
Completed NCT01114958 - Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases Phase 1
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Completed NCT02926768 - Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Phase 1
Not yet recruiting NCT02907606 - Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study N/A
Active, not recruiting NCT02514512 - Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking N/A
Completed NCT02531737 - Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer Phase 2
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Active, not recruiting NCT02284633 - Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
Completed NCT02106143 - RejuvenAirâ„¢ System Lobectomy Safety and Histology Study N/A
Completed NCT01933789 - Improving Communication About Serious Illness N/A
Enrolling by invitation NCT01687647 - Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure Phase 3
Completed NCT00243685 - Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Phase 2/Phase 3
Completed NCT00351962 - Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours N/A
Terminated NCT00356525 - Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor Phase 2
Completed NCT00385177 - Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors Phase 1
Withdrawn NCT00090701 - A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer Phase 2
Recruiting NCT01789229 - Establishment of a Tumor Bank for Tissue Samples
Completed NCT00069160 - Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer Phase 2